SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending after a strong earnings report and news of a massive AI lease deal, positioning the company as a key player in AI infrastructure. The community is excited about the potential for a short squeeze and analysts raising price targets, while also debating entry points and long-term prospects. Bullish sentiment is fueled by the company's growth in the AI data center space, with some comparing it to other high-flying stocks in the sector.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ ($LAES) is surging due to a strategic partnership focused on developing quantum-resistant chips for U.S. defense applications, fueling speculation about lucrative government contracts. The community is buzzing about the company's growth potential and comparing it to other players in the quantum computing space, with some investors believing LAES is undervalued and predicting a significant climb.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is gaining traction as community members express excitement, referencing an imminent listing on Moonshot and calling for others to "RAGE" harder. Fueling the hype, some are alluding to potential breakouts and increased liquidity, while others point to the project's roots in OG internet meme culture. The community's focus remains on strong community building and promoting the idea of everyone making it.

GSR III Acquisition Corp engages in the merger, share exchange, asset acquisition, share purchase or reorganization with one or more businesses. The company was founded on May 10, 2023 and is headquartered in Austin, Texas.

GSR III Acquisition Corp. - Ordinary Shares- Class A

GSR III Acquisition Corp. Ordinary Shares

GSRT is trending due to the imminent ticker change to NKLR following its merger with Terra Innovatum, a micro-modular nuclear reactor developer; the change is expected to occur soon. Community members are excited about the potential, drawing comparisons to OKLO and highlighting the growing demand for nuclear energy. Discussions also include the stock's valuation relative to its peers and expectations for increased volume and volatility post-ticker change.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as the community discusses its potential for significant growth, drawing comparisons to IREN's valuation and anticipating news related to AI/HPC ventures. Bullish sentiment is fueled by the company's strong Bitcoin holdings, infrastructure ownership, and a recent mining update, with many expecting a run to higher price targets. Additionally, some are speculating on government involvement and the potential for a short squeeze.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as chatter increases around a potential short squeeze, with the community noting high short interest and open call option volume. Recent developments, including a major financial endorsement and increased stake from Alphabet Inc., have boosted optimism. Discussions also involve TeraWulf's shift towards AI and high-performance computing, similar to peers in the sector.

One and one Green Technologies. Inc - Ordinary Shares - Class A

YDDL is trending due to its recent IPO and subsequent volatile price action, with the stock experiencing significant gains and drops. The community is actively discussing its low float, high insider ownership, and potential for both further gains and significant losses, with some expressing concerns about it being a pump and dump. Some traders are also looking at other AI and Green Tech names like $APLD and $HIVE.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust ($SLV) is trending as silver prices approach multi-decade highs, sparking discussions about a potential breakout. Community members are actively discussing the possibility of a short squeeze and the impact of supply deficits on prices. Some analysts point to a long-term cup and handle formation, suggesting a bullish outlook, while others debate potential pullbacks and profit-taking opportunities.

Zoracles

Zoracles ($ZORA) is trending due to a recent listing on Robinhood, driving increased volume and attention from new investors. The community is excited about the potential exposure to Robinhood's user base and the possibility of further listings on major exchanges. Some community members are drawing comparisons to social media platforms and anticipating a broader altcoin season.

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

CMCT is trending as traders discuss its potential for a short squeeze and parabolic moves, given its low float. Community members are debating its volatile history, reverse splits, and the possibility of a pump and dump, while also noting its current uptrend. Some traders are speculating about a potential break above key price levels that could trigger further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

H.C. Wainwright raised its price target on AnaptysBio (ANAB) to $59 from $38 on Tuesday, following the company's announcement of its plan to split its business into two.The analyst kept a ‘Buy’ rating on the shares. The new price target implies a potential upside of about 154% to the stock’s closing price on Monday.AnaptysBio <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-intent-separate-biopharma-operations">stated </a>on Tuesday that its board of directors approved plans to explore separating its business into two independent, publicly traded companies. Upon completion of the split, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and Imsidolimab with Vanda, with a focus on protecting and returning their value, the company said.The royalty management company is expected to require minimal infrastructure and staff, and will operate under a new name, it added.Meanwhile, the other company, referred to as Biopharma Co., will focus on biopharmaceutical operations, including the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, such as Rosnilimab, ANB033, and ANB101. After the split, Biopharma Co. will launch with adequate capital to fund operations for at least two years and will also operate under a new name, the company stated.The separation is expected to be completed by the end of 2026. Anaptys CEO Daniel Faga is expected to continue as CEO of the biopharma company.Shares of the company traded 30% higher on Tuesday afternoon at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANAB">ANAB stock</a> rose from ‘bullish’ to ‘extremely bullish territory’ over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_12_21_38_PM_png_239792a64d.webp" alt="ANAB's Sentiment Meter and Message Volume as of 12:21 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>ANAB's Sentiment Meter and Message Volume as of 12:21 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they now expect the stock to crater.<stembedurl>https://stocktwits.com/CommercialREbroker/message/630482537</stembedurl>ANAB stock has more than doubled this year but dropped nearly 10% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-amends-deal-with-sanofi-broadens-partnership/chDDB6dR3BH">Novavax Amends Deal With Sanofi, Broadens Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen in Athens, Greece on January 13, 2023. (Photo illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level

H.C. Wainwright’s new price target of $59 implies a potential upside of about 154% to the stock’s closing price on Monday. 

Equity

Eli Lilly shares fell 0.6% in premarket trading on Wednesday as safety concerns tied to its rheumatoid arthritis drug peresolimab and mixed results from its obesity pill candidate orforglipron weighed on investor appetite.&nbsp;In the 72-week ATTAIN-1 study, orforglipron met its main goal of superior weight reduction over placebo across all three tested doses. Patients on the highest 36 mg dose lost an average of 27.3 pounds, or 12.4% of their body weight, compared with just 2.2 pounds, or 0.9%, on placebo. Almost six in ten people shed at least 10% of their weight, and about four in ten lost 15% or more.Among the 1,127 participants with prediabetes at enrollment, up to 91% of those on treatment achieved near-normal blood sugar levels at 72 weeks, compared with 42% on placebo. The trial also showed improvements in waist circumference, cholesterol, triglycerides, blood pressure, and inflammation markers.&nbsp;However, weight loss plateaued for most patients. Researchers noted that despite the 72-week duration, weight reduction was not greater than in the prior Phase 2 trial, possibly due to differences in trial design, including greater geographic diversity and a higher proportion of male participants.The main side effects were mild-to-moderate stomach issues such as nausea, constipation, diarrhea and vomiting, with between 5.3% and 10.3% of patients stopping treatment, compared with 2.7% on placebo. No liver safety signals were seen.Orforglipron, licensed from Chugai in 2018, is also in late-stage studies for type 2 diabetes, sleep apnea and hypertension. Lilly said more than 4,500 people are enrolled in its Phase 3 ATTAIN program and that a filing in diabetes is planned for 2026.TD Cowen Downplays Peresolimab ReactionSeparately, TD Cowen analysts said Tuesday that the market reaction to Eli Lilly’s peresolimab data “seems excessive,” noting that AnaptysBio’s rival PD-1 agonist rosnilimab has reported no malignancies in any of its trials.Lilly halted development of peresolimab, an experimental PD-1 agonist for rheumatoid arthritis, after a Phase IIb study raised safety concerns. While the drug was superior to placebo at week 12 across several key endpoints, its efficacy was not clearly differentiated from existing therapies.&nbsp;In addition, malignancies were reported in patients receiving peresolimab, including two cases in each of the 1,000 mg and 400 mg dose groups through week 12, and four more cases by week 60, compared with none in the placebo arm.&nbsp;Reports of possible major cardiovascular events also weighed on the program’s benefit–risk profile and contributed to the decision to stop development.On Stocktwits, retail sentiment for Lilly was ‘bearish’ amid ‘low’ message volume.<a href="https://stocktwits.com/symbol/LLY">Lilly’s stock</a> has declined 0.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Why Is Eli Lilly’s Stock Slipping Premarket?

The drugmaker’s oral GLP-1 pill orforglipron showed mixed data in a Phase 3 trial, and regulatory filing for obesity is targeted as early as next year.

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of +10.67% and +36.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio Inc.’s shares rose to a six-month high on Tuesday following the announcement of successful Phase 2b results from testing their experimental rheumatoid arthritis medication rosnilimab.The stock closed 7.6% higher at $23.52 on Tuesday, extending gains by another 5.1% to $24.71 in after-hours trading.A trial involving 424 patients proved that rosnilimab, a PD-1+ T cell depleter and agonist, delivered similar effectiveness to JAK inhibitors when administered&nbsp;monthly.&nbsp;Patients saw significant disease activity improvements through reductions in the Clinical Disease Activity Index (CDAI) and ACR70 response rates, which lasted for six months.The treatment-free period of up to two months showed sustained patient responses, which signals the possibility for longer dosing intervals.&nbsp;According to the company, no serious treatment-related adverse events appeared during the study, and the drug demonstrated superior tolerability compared to existing biologics and JAK inhibitors.On Stocktwits, retail sentiment was ‘bearish’ amid ‘extremely high’ message volume.One user&nbsp;suggested the stock was being "pumped" and speculated that a direct offering might follow.&nbsp;<stembedurl>https://stocktwits.com/Yukinvestor/message/616705356</stembedurl>Another user said they expected the updated data to disappoint and anticipated a potential offering.<stembedurl>https://stocktwits.com/Yukinvestor/message/616686959</stembedurl>The stock has risen 76.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an AnaptysBio logo seen displayed on a smartphone screen on a desk next to a Macbook in Athens, Greece on November 12, 2022. (Photo Illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering

The company reported successful mid-stage results for its rheumatoid arthritis drug rosnilimab, which matched the efficacy of JAK inhibitors with fewer side effects.

What’s the role of generative AI in drug discovery?

Investing.com -- Generative AI is emerging as a transformative long-term force in drug discovery, a field historically characterized by lengthy timelines, high costs, and low success rates.

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist Vanda Pharmaceuticals and Anaptys Announce...

Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking the stock’s steepest single-day loss since March 2021.&nbsp;The collapse followed the company’s announcement that it would halt further investment in its experimental therapy ANB032 after the drug failed to meet primary and secondary endpoints in a Phase 2b trial for moderate-to-severe atopic dermatitis, commonly known as eczema.Wednesday’s drop pushed AnaptysBio stock to its lowest closing level since December 2023, intensifying concerns among retail investors.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_12_at_5_59_31_PM_c4fa8def22.png" alt="Screenshot 2024-12-12 at 5.59.31 PM.png" width="1318" height="324"><figcaption>ANAB sentiment meter and message volume on Dec 12 premarket as of 7:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for AnaptysBio plunged into ‘extremely bearish’ levels before the bell on Thursday, following a 20% jump in message volume in the previous session.<stembedurl>https://stocktwits.com/SurdifiedStocks/message/596025184</stembedurl><stembedurl>https://stocktwits.com/Blossom_Tradez/message/595998006</stembedurl>AnaptysBio stated that it would redirect its resources and capital toward other investigational autoimmune therapies.&nbsp;The company plans to report top-line Phase 2b data for rosnilimab in rheumatoid arthritis by February 2025 and Phase 2 data for ulcerative colitis in the first quarter of 2026.Wall Street analysts quickly adjusted their outlooks. H.C. Wainwright downgraded the stock to ‘Neutral’ from ‘Buy,’ slashing its price target from $52 to $19.&nbsp;The brokerage expressed disappointment but not surprise, citing the high-risk nature of the ANB032 program. It also lowered its probability of success estimates for rosnilimab in rheumatoid arthritis from 50% to 40% and for ulcerative colitis from 40% to 30%.Wells Fargo analyst Derek Archila lowered the firm’s price target for AnaptysBio to $40 from $56 but maintained an ‘Overweight’ rating.&nbsp;Archila noted that while the Phase 2b trial’s failure aligns with their bear-case scenario, the shares’ current valuation offers a favorable risk/reward profile ahead of upcoming Phase 2 data releases.AnaptysBio's stock has lost over 28% year-to-date as of Wednesday’s close, with the latest developments adding further pressure on its stock performance and investor confidence.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen with a computer wallpaper in the background in Athens, Greece on May 5, 2021. (Photo by Nikolas Kokovlis/NurPhoto via Getty Images)

AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated

Wednesday’s drop pushed AnaptysBio stock to its lowest closing level since December 2023, intensifying concerns among retail investors.

A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts

Latest Ratings for ANAB
 DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Jun 2021HC Wainwright & Co.Initiates Coverage OnBuy May 2021UBSInitiates Coverage OnNeutral
 View More...

What Analysts Are Saying About AnaptysBio Stock

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

AnaptysBio Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

ANAB
AnaptysBio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANAB News

ANABAnaptysBio Inc